Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and ...

Key Takeaways Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Just like when you find a glitzy resort in your dream destination, your first question about weight loss drugs might be, how ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

Researchers urged caution, recommending that diabetic patients on GLP-1 therapies undergo regular eye screening….